Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang, Shengqing Gu, Deng Pan, et al.
Nature Medicine (2018) Vol. 24, Iss. 10, pp. 1550-1558
Open Access | Times Cited: 3896

Showing 1-25 of 3896 citing articles:

TIMER2.0 for analysis of tumor-infiltrating immune cells
Taiwen Li, Jingxin Fu, Zexian Zeng, et al.
Nucleic Acids Research (2020) Vol. 48, Iss. W1, pp. W509-W514
Open Access | Times Cited: 3740
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Timothy A. Chan, Mark Yarchoan, Elizabeth M. Jaffee, et al.
Annals of Oncology (2018) Vol. 30, Iss. 1, pp. 44-56
Open Access | Times Cited: 2264
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
Bagher Farhood, Masoud Najafi, Keywan Mortezaee
Journal of Cellular Physiology (2018) Vol. 234, Iss. 6, pp. 8509-8521
Closed Access | Times Cited: 1321
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Rong Tang, Jin Xu, Bo Zhang, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 976
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro, Pablo Sarobe, Sandra Hervás‐Stubbs, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 8, pp. 525-543
Open Access | Times Cited: 938
Large-scale public data reuse to model immunotherapy response and resistance
Jingxin Fu, Karen Li, Wubing Zhang, et al.
Genome Medicine (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 824
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal, Elizabeth Larose Cadieux, Roberto Salgado, et al.
Nature (2019) Vol. 567, Iss. 7749, pp. 479-485
Open Access | Times Cited: 781
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu, Bastian Schilling, Derek Liu, et al.
Nature Medicine (2019) Vol. 25, Iss. 12, pp. 1916-1927
Open Access | Times Cited: 773
ImmuCellAI: A Unique Method for Comprehensive T‐Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy
Ya‐Ru Miao, Qiong Zhang, Qian Lei, et al.
Advanced Science (2020) Vol. 7, Iss. 7
Open Access | Times Cited: 766
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
Martin McLaughlin, Emmanuel C. Patin, Malin Pedersen, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 4, pp. 203-217
Closed Access | Times Cited: 625
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4
Peng Liao, Weimin Wang, Weichao Wang, et al.
Cancer Cell (2022) Vol. 40, Iss. 4, pp. 365-378.e6
Open Access | Times Cited: 521
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Imran G. House, Peter Savas, Junyun Lai, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 2, pp. 487-504
Open Access | Times Cited: 509
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng Fu, Minru Liao, Rui Qin, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 487
RNA sequencing: new technologies and applications in cancer research
Mingye Hong, Shuang Tao, Ling Zhang, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 417
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan, Kelly P. Burke, Eliezer M. Van Allen
Nature Medicine (2019) Vol. 25, Iss. 3, pp. 389-402
Open Access | Times Cited: 413
Ferroptosis in cancer and cancer immunotherapy
Lei Zhao, Xiaoxue Zhou, Feng Xie, et al.
Cancer Communications (2022) Vol. 42, Iss. 2, pp. 88-116
Open Access | Times Cited: 411
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
Joseph L. Benci, Lexus R. Johnson, Ruth Choa, et al.
Cell (2019) Vol. 178, Iss. 4, pp. 933-948.e14
Open Access | Times Cited: 399
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Rilan Bai, Zheng Lv, Dongsheng Xu, et al.
Biomarker Research (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 388
Multi-omic machine learning predictor of breast cancer therapy response
Stephen‐John Sammut, Mireia Crispin‐Ortuzar, Suet‐Feung Chin, et al.
Nature (2021) Vol. 601, Iss. 7894, pp. 623-629
Open Access | Times Cited: 357
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Kobe Yuen, Lifen Liu, Vinita Gupta, et al.
Nature Medicine (2020) Vol. 26, Iss. 5, pp. 693-698
Open Access | Times Cited: 350
Stromal cell diversity associated with immune evasion in human triple‐negative breast cancer
Sunny Z. Wu, Daniel Roden, Chenfei Wang, et al.
The EMBO Journal (2020) Vol. 39, Iss. 19
Open Access | Times Cited: 341
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Cancer Cell (2020) Vol. 38, Iss. 4, pp. 500-515.e3
Open Access | Times Cited: 295
Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer
Anqi Lin, Jian Zhang, Peng Luo
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 276
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
Jiao Hu, Anze Yu, Belaydi Othmane, et al.
Theranostics (2021) Vol. 11, Iss. 7, pp. 3089-3108
Open Access | Times Cited: 276
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
Yang Gao, Naoe Taira Nihira, Xia Bu, et al.
Nature Cell Biology (2020) Vol. 22, Iss. 9, pp. 1064-1075
Open Access | Times Cited: 273
Page 1 - Next Page

Scroll to top